CASP12: A Drug Target / Disease Biomarker (G100506742)

Target Name: CASP12

NCBI ID: G100506742

CASP12

CASP12: A Drug Target / Disease Biomarker

CASP12, short for carcinoembryonic antigen 12, is a protein that is expressed in a variety of tissues, including the brain, pancreas, and gastrointestinal tract. It is also a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The protein encoded by the CASP12 gene is a single transmembrane protein that consists of an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is responsible for the protein's ability to interact with various cell surface receptors, while the transmembrane domain is responsible for the protein's ability to span the cell membrane and interact with intracellular signaling pathways. The intracellular domain is responsible for the protein's ability to interact with various intracellular signaling pathways, including the PI3K/Akt signaling pathway.

CASP12 has been shown to play a role in several cellular processes, including cell signaling, cell adhesion, and cell survival. It has been shown to interact with several intracellular signaling pathways, including the PI3K/Akt signaling pathway, which is involved in the regulation of cell signaling and cell survival.

One of the most promising aspects of CASP12 is its potential as a drug target. Several studies have shown that inhibiting the activity of CASP12 can lead to the inhibition of various cellular processes, including cell signaling, cell adhesion, and cell survival. This suggests that CASP12 could be an effective target for the treatment of diseases that are characterized by these processes, such as cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its potential as a drug target, CASP12 has also been shown to be a potential biomarker for several diseases. Its expression has been shown to be elevated in a variety of tissues and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that the activity of CASP12 could be a useful diagnostic tool for these diseases, as well as for tracking the effectiveness of potential therapeutic interventions.

CASP12 is also a potential target for several other therapeutic approaches, including small molecule inhibitors and monoclonal antibodies. Several studies have shown that inhibiting the activity of CASP12 using small molecules or monoclonal antibodies can lead to the inhibition of various cellular processes, including cell signaling, cell adhesion, and cell survival. This suggests that these therapeutic approaches could be effective in treating diseases that are characterized by these processes.

In conclusion, CASP12 is a protein that has the potential to be a drug target and biomarker for several diseases. Its interaction with the PI3K/Akt signaling pathway makes it an attractive target for the treatment of diseases that are characterized by the regulation of cell signaling and cell survival. Further research is needed to fully understand the role of CASP12 in cellular processes and its potential as a therapeutic approach.

Protein Name: Caspase 12 (gene/pseudogene)

Functions: Has no protease activity. May reduce cytokine release in response to bacterial lipopolysaccharide during infections. Reduces activation of NF-kappa-B in response to TNF

The "CASP12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CASP12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets